Here is a list of 102 papers coauthored by Lalezar
Post# of 148182
(Total Views: 793)
Posted On: 03/13/2020 8:56:07 AM
Here is a list of 102 papers coauthored by Lalezari, most results of clinical trials, including every single ccr5 inhibitor going back 20 years, including pro-140 before CytoDyn took over and maraviroc, even some most haven't heard: tbr-652 and BMS-378806. He is listed now as the PI for the mTNBC trial. He is the most experienced person on the planet with clinical applications and connections of ccr5 imo. Great addition..
https://www.ncbi.nlm.nih.gov/pubmed/?term=Lal...d=26423650
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Lalezari JP, Latiff GH, Brinson C, Echevarría J, Treviño-Pérez S, Bogner JR, Thompson M, Fourie J, Sussmann Pena OA, Mendo Urbina FC, Martins M, Diaconescu IG, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team.
Lancet HIV. 2015 Oct;2(10):e427-37. doi: 10.1016/S2352-3018(15)00177-0. Epub 2015 Sep 1.
PMID:
26423650
Similar articles
Select item 25942724
2.
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD.
JAMA. 2015 May 5;313(17):1736-44. doi: 10.1001/jama.2015.3868.
PMID:
25942724
Free Article
Similar articles
Select item 25839406
3.
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, Aguilar H, Felizarta F, McGovern B, King M, Polepally AR, Cohen DE.
J Hepatol. 2015 Aug;63(2):364-9. doi: 10.1016/j.jhep.2015.03.029. Epub 2015 Apr 1.
PMID:
25839406
Free Article
Similar articles
Select item 25038354
4.
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D; PHOTON-1 Investigators.
JAMA. 2014 Jul 23-30;312(4):353-61. doi: 10.1001/jama.2014.7734. Erratum in: JAMA. 2014 Nov 12;312(18):1932.
PMID:
25038354
Free PMC Article
Similar articles
Select item 23439365
5.
IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
Lalezari J, Box T, O'Riordan W, Mehra P, Nguyen T, Poordad F, Dejesus E, Kwo P, Godofsky E, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai J, Mayers D.
Antivir Ther. 2013;18(6):755-64. doi: 10.3851/IMP2552. Epub 2013 Feb 25.
PMID:
23439365
Similar articles
Select item 23070151
6.
Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection.
Lalezari J, Asmuth D, Casiró A, Vargas H, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai J, Mayers D.
Antimicrob Agents Chemother. 2012 Dec;56(12):6372-8. doi: 10.1128/AAC.01521-12. Epub 2012 Oct 15.
PMID:
23070151
Free PMC Article
Similar articles
Select item 25251156
7.
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.
Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, Freilich B, Zamparo J, Brown K, Dimitrova D, Kumar M, Manion D, Heath-Chiozzi M, Wolf R, Hughes E, Muir AJ, Hernandez AF.
Hepatology. 2015 Aug;62(2):409-16. doi: 10.1002/hep.27488. Epub 2015 May 26.
PMID:
25251156
Similar articles
Select item 25394038
8.
HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis.
Brinson C, Lalezari J, Gulam LH, Thompson M, Echevarria J, Treviño-Pérez S, Stock D, Samit JR, George HJ, Lataillade M.
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19529. doi: 10.7448/IAS.17.4.19529. eCollection 2014.
PMID:
25394038
Free PMC Article
Similar articles
Select item 21317794
9.
Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects.
Lalezari J, Gathe J, Brinson C, Thompson M, Cohen C, Dejesus E, Galindez J, Ernst JA, Martin DE, Palleja SM.
J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25. doi: 10.1097/QAI.0b013e318213c2c0.
PMID:
21317794
Similar articles
Select item 17617270
10.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B; DUET-1 study group.
Lancet. 2007 Jul 7;370(9581):29-38.
PMID:
17617270
Similar articles
Select item 16280695
11.
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP.
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):413-21.
PMID:
16280695
Similar articles
Select item 12138345
12.
A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
Lalezari J, Lindley J, Walmsley S, Kuppermann B, Fisher M, Friedberg D, Lalonde R, Matheron S, Nieto L, Torriani FJ, Van Syoc R, Sutton MA, Buhles W, Stempien MJ; Roche Valganciclovir Study Group.
J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):392-400.
PMID:
12138345
Similar articles
Select item 16135896
13.
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, Shachoy-Clark A, Adkison K, Demarest J, Lou Y, Berrey M, Piscitelli S.
AIDS. 2005 Sep 23;19(14):1443-8.
PMID:
16135896
Similar articles
Select item 25394039
14.
Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis.
Lalezari J, Latiff GH, Brinson C, Echevarria J, Treviño-Pérez S, Bogner JR, Stock D, Joshi SR, Hanna GJ, Lataillade M.
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19530. doi: 10.7448/IAS.17.4.19530. eCollection 2014.
PMID:
25394039
Free PMC Article
Similar articles
Select item 20935557
15.
Hepatic safety and tolerability in the maraviroc clinical development program.
Ayoub A, Alston S, Goodrich J, Heera J, Hoepelman AI, Lalezari J, Mchale M, Nelson M, van der Ryst E, Mayer H.
AIDS. 2010 Nov 13;24(17):2743-50. doi: 10.1097/QAD.0b013e32833f9ce2.
PMID:
20935557
Similar articles
Select item 19710593
16.
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups.
AIDS. 2009 Nov 13;23(17):2289-300. doi: 10.1097/QAD.0b013e3283316a5e.
PMID:
19710593
Similar articles
Select item 20134329
17.
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
Towner W, Lalezari J, Sension MG, Wohlfeiler M, Gathe J, Appelbaum JS, Bellman P, Gottlieb MS, Ryan R, Nijs S, Hoogstoel A, Van Solingen-Ristea R, Witek J.
J Acquir Immune Defic Syndr. 2010 Apr;53(5):614-8. doi: 10.1097/QAI.0b013e3181cdebb1.
PMID:
20134329
Similar articles
Select item 20300008
18.
Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.
Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C, Deeks SG.
J Acquir Immune Defic Syndr. 2010 Aug;54(4):389-93. doi: 10.1097/QAI.0b013e3181c42ea4.
PMID:
20300008
Free PMC Article
Similar articles
Select item 21078951
19.
Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
Hanna GJ, Lalezari J, Hellinger JA, Wohl DA, Nettles R, Persson A, Krystal M, Lin P, Colonno R, Grasela DM.
Antimicrob Agents Chemother. 2011 Feb;55(2):722-8. doi: 10.1128/AAC.00759-10. Epub 2010 Nov 15.
PMID:
21078951
Free PMC Article
Similar articles
Select item 19219022
20.
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.
Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA.
Nat Med. 2009 Mar;15(3):285-92. doi: 10.1038/nm.1932. Epub 2009 Feb 15.
PMID:
19219022
21.
Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.
N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.
PMID:
18832244
Free PMC Article
Similar articles
Select item 18266604
22.
Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
Lalezari J, Yadavalli GK, Para M, Richmond G, Dejesus E, Brown SJ, Cai W, Chen C, Zhong J, Novello LA, Lederman MM, Subramanian GM.
J Infect Dis. 2008 Mar 1;197(5):721-7. doi: 10.1086/527327.
PMID:
18266604
Similar articles
Select item 18315507
23.
Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection.
Jariwalla RJ, Lalezari J, Cenko D, Mansour SE, Kumar A, Gangapurkar B, Nakamura D.
J Altern Complement Med. 2008 Mar;14(2):139-46. doi: 10.1089/acm.2006.6397.
PMID:
18315507
Similar articles
Select item 26636929
24.
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.
Thompson M, Saag M, DeJesus E, Gathe J, Lalezari J, Landay AL, Cade J, Enejosa J, Lefebvre E, Feinberg J.
AIDS. 2016 Mar 27;30(6):869-78. doi: 10.1097/QAD.0000000000000988.
PMID:
26636929
Free PMC Article
Similar articles
Select item 25706092
25.
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T.
JAMA. 2015 Mar 24-31;313(12):1223-31. doi: 10.1001/jama.2015.1328.
PMID:
25706092
Similar articles
Select item 23183528
26.
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, Cornpropst MT, Mader M, Albanis E, Jiang D, Hebner CM, Symonds WT, Berrey MM, Lalezari J.
J Hepatol. 2013 Apr;58(4):663-8. doi: 10.1016/j.jhep.2012.11.018. Epub 2012 Nov 23.
PMID:
23183528
Similar articles
Select item 23717490
27.
A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.
Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Korman AJ, Lowy I.
PLoS One. 2013 May 22;8(5):e63818. doi: 10.1371/journal.pone.0063818. Print 2013.
PMID:
23717490
Free PMC Article
Similar articles
Select item 23797691
28.
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
Taiwo B, Acosta EP, Ryscavage P, Berzins B, Lu D, Lalezari J, Castro J, Adeyemi O, Kuritzkes DR, Eron JJ, Tsibris A, Swindells S.
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):167-73. doi: 10.1097/QAI.0b013e3182a03d95.
PMID:
23797691
Free PMC Article
Similar articles
Select item 22738014
29.
Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects.
Hicks C, Clay P, Redfield R, Lalezari J, Liporace R, Schneider S, Sension M, McRae M, Laurent JP.
AIDS Res Hum Retroviruses. 2013 Feb;29(2):250-5. doi: 10.1089/AID.2012.0093. Epub 2012 Aug 27.
PMID:
22738014
Free PMC Article
Similar articles
Select item 21716073
30.
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, Stroder R, Chen S, Underwood M, Fujiwara T, Piscitelli S, Lalezari J.
AIDS. 2011 Sep 10;25(14):1737-45. doi: 10.1097/QAD.0b013e32834a1dd9.
PMID:
21716073
Similar articles
Select item 26423374
31.
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M.
Lancet HIV. 2015 Aug;2(
:e319-27. doi: 10.1016/S2352-3018(15)00114-9. Epub 2015 Jul 9. Erratum in: Lancet HIV. 2015 Aug;2( :e316. Lancet HIV. 2015 Oct;2(10):e416.
PMID:
26423374
Similar articles
Select item 23499158
32.
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A.
Lancet Infect Dis. 2013 May;13(5):401-8. doi: 10.1016/S1473-3099(13)70033-1. Epub 2013 Mar 15.
PMID:
23499158
Similar articles
Select item 11590500
33.
Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
Lalezari JP, Beal JA, Ruane PJ, Cohen CJ, Jacobson EL, Sundin D, Leong WP, Raffanti SP, Wheeler DA, Anderson RD, Keiser P, Schrader SR, Goodgame JC, Steinhart CR, Murphy RL, Wolin MJ, Smith KA.
HIV Clin Trials. 2000 Nov-Dec;1(3):1-15.
PMID:
11590500
Similar articles
Select item 9036797
34.
Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial.
Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL, Jaffe HS.
Ann Intern Med. 1997 Feb 15;126(4):257-63.
PMID:
9036797
Similar articles
Select item 9525435
35.
Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS.
Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, Nelson R, Hardy WD, Kuppermann BD, Northfelt DW, Youle M, Johnson M, Lewis RA, Weinberg DV, Simon GL, Wolitz RA, Ruby AE, Stagg RJ, Jaffe HS.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):339-44.
PMID:
9525435
Similar articles
Select item 7769276
36.
Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group.
Spector SA, Busch DF, Follansbee S, Squires K, Lalezari JP, Jacobson MA, Connor JD, Jung D, Shadman A, Mastre B, et al.
J Infect Dis. 1995 Jun;171(6):1431-7.
PMID:
7769276
Similar articles
Select item 25395187
37.
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, Sundaraiyer V, Natuk R, Gurtman A, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
J Infect Dis. 2015 Jul 1;212(1):18-27. doi: 10.1093/infdis/jiu631. Epub 2014 Nov 13.
PMID:
25395187
Similar articles
Select item 18279104
38.
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.
Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ, Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE, Choudhri S.
J Interferon Cytokine Res. 2008 Feb;28(2):89-100. doi: 10.1089/jir.2007.0064.
PMID:
18279104
Similar articles
Select item 27188960
39.
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Kowdley KV, Nelson DR, Lalezari JP, Box T, Gitlin N, Poleynard G, Rabinovitz M, Ravendhran N, Sheikh AM, Siddique A, Bhore R, Noviello S, Rana K.
Liver Int. 2016 Nov;36(11):1611-1618. doi: 10.1111/liv.13165. Epub 2016 Jun 16.
PMID:
27188960
Similar articles
Select item 27922453
40.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
Thompson M, Lalezari JP, Kaplan R, Pinedo Y, Pena OAS, Cahn P, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team.
Antivir Ther. 2017;22(3):215-223. doi: 10.3851/IMP3112. Epub 2016 Dec 6.
PMID:
27922453
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group.
N Engl J Med. 2003 May 29;348(22):2175-85. Epub 2003 Mar 13. Erratum in: N Engl J Med. 2003 Sep 11;349(11):1100.
PMID:
12637625
Free Article
Similar articles
Select item 18507525
42.
An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).
Lalezari JP, Saag M, Walworth C, Larson P.
AIDS Res Hum Retroviruses. 2008 Jun;24(6):805-13. doi: 10.1089/aid.2007.0251.
PMID:
18507525
Similar articles
Select item 17491001
43.
Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.
Lalezari JP, Ward DJ, Tomkins SA, Garges HP.
J Antimicrob Chemother. 2007 Jul;60(1):170-4. Epub 2007 May 8.
PMID:
17491001
Similar articles
Select item 16433107
44.
Enfuvirtide for nurses: answering patient questions on activity, safety, and lifestyle impact.
Glutzer E, Lalezari JP.
J Assoc Nurses AIDS Care. 2005 Sep-Oct;16(5):26-34. Review.
PMID:
16433107
Similar articles
Select item 15747252
45.
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
Lalezari JP, Bellos NC, Sathasivam K, Richmond GJ, Cohen CJ, Myers RA Jr, Henry DH, Raskino C, Melby T, Murchison H, Zhang Y, Spence R, Greenberg ML, Demasi RA, Miralles GD; T1249-102 Study Group.
J Infect Dis. 2005 Apr 1;191(7):1155-63. Epub 2005 Feb 22.
PMID:
15747252
Similar articles
Select item 15148534
46.
Enfuvirtide.
Lalezari JP, Luber AD.
Drugs Today (Barc). 2004 Mar;40(3):259-69. Review.
PMID:
15148534
Similar articles
Select item 14518696
47.
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J.
Antivir Ther. 2003 Aug;8(4):279-87.
PMID:
14518696
Similar articles
Select item 12957192
48.
Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
Lalezari JP, Patel IH, Zhang X, Dorr A, Hawker N, Siddique Z, Kolis SJ, Kinchelow T.
J Clin Virol. 2003 Oct;28(2):217-22.
PMID:
12957192
Similar articles
Select item 12765160
49.
Clinical safety and efficacy of enfuvirtide (T-20), a new fusion inhibitor. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
Lalezari JP.
AIDS Read. 2003 Mar;13(3 Suppl):S9-13.
PMID:
12765160
Similar articles
Select item 12646792
50.
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM.
AIDS. 2003 Mar 28;17(5):691-8.
PMID:
12646792
Similar articles
Select item 11744430
51.
High dose oral ganciclovir treatment for cytomegalovirus retinitis.
Lalezari JP, Friedberg DN, Bissett J, Giordano MF, Hardy WD, Drew WL, Hubbard LD, Buhles WC, Stempien MJ, Georgiou P, Jung DT, Robinson CA; Roche Cooperative Oral Ganciclovir Study Group.
J Clin Virol. 2002 Feb;24(1-2):67-77.
PMID:
11744430
Similar articles
Select item 12183255
52.
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.
Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, Talarico CL, Shaw S, Jacobson MA, Drew WL.
Antimicrob Agents Chemother. 2002 Sep;46(9):2969-76.
PMID:
12183255
Free PMC Article
Similar articles
Select item 11176734
53.
Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials.
Lalezari J, Campion K, Keene O, Silagy C.
Arch Intern Med. 2001 Jan 22;161(2):212-7.
PMID:
11176734
Similar articles
Select item 9395363
54.
The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.
Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffe HS, Mulato AS, Lamy PD, Li W, Cherrington JM, Hellmann N, Kahn J.
J Infect Dis. 1997 Dec;176(6):1517-23.
PMID:
9395363
Similar articles
Select item 9333146
55.
A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.
Lalezari J, Schacker T, Feinberg J, Gathe J, Lee S, Cheung T, Kramer F, Kessler H, Corey L, Drew WL, Boggs J, McGuire B, Jaffe HS, Safrin S.
J Infect Dis. 1997 Oct;176(4):892-8.
PMID:
9333146
Similar articles
Select item 25394009
56.
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
Eron JJ, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C, Elion R, Blick G, Khatri A, Hu YB, Gibbons K, Fredrick L, Co M, D'Amico R, Da Silva-Tillmann B, Trinh R, Sulkowski MS.
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19500. doi: 10.7448/IAS.17.4.19500. eCollection 2014.
PMID:
25394009
Free PMC Article
Similar articles
Select item 9058615
57.
Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis.
Lalezari JP, Kuppermann BD.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14 Suppl 1:S27-31. Review.
PMID:
9058615
Similar articles
Select item 18433307
58.
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group.
Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993.
PMID:
18433307
Similar articles
Select item 20710052
59.
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
DeJesus E, Lalezari JP, Osiyemi OO, Ruane PJ, Ryan R, Kakuda TN, Witek J.
Antivir Ther. 2010;15(5):711-20. doi: 10.3851/IMP1562.
PMID:
20710052
Similar articles
Select item 24725238
60.
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators.
N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.
PMID:
24725238
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T.
PLoS Pathog. 2014 Apr 10;10(4):e1004071. doi: 10.1371/journal.ppat.1004071. eCollection 2014 Apr.
PMID:
24722454
Free PMC Article
Similar articles
Select item 9058614
62.
Cidofovir: a new therapy for cytomegalovirus retinitis.
Lalezari JP.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14 Suppl 1:S22-6. Review.
PMID:
9058614
Similar articles
Select item 16280694
63.
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP.
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12.
PMID:
16280694
Similar articles
Select item 27456384
64.
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ.
Gastroenterology. 2016 Oct;151(4):651-659.e1. doi: 10.1053/j.gastro.2016.07.020. Epub 2016 Jul 25.
PMID:
27456384
Similar articles
Select item 7859141
65.
Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients.
Drew WL, Anderson R, Lang W, Miner RC, Davis G, Lalezari J.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):289-91.
PMID:
7859141
Similar articles
Select item 17711378
66.
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP.
AIDS Patient Care STDS. 2007 Aug;21( :533-43.
PMID:
17711378
Similar articles
Select item 8618603
67.
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.
Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, Sparti PD, Havlir DV, Simpson G, Buhles W, Wong R, Stempien M.
N Engl J Med. 1996 Jun 6;334(23):1491-7.
PMID:
8618603
Free Article
Similar articles
Select item 30625297
68.
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.
Yuen MF, Gane EJ, Kim DJ, Weilert F, Yuen Chan HL, Lalezari J, Hwang SG, Nguyen T, Flores O, Hartman G, Liaw S, Lenz O, Kakuda TN, Talloen W, Schwabe C, Klumpp K, Brown N.
Gastroenterology. 2019 Apr;156(5):1392-1403.e7. doi: 10.1053/j.gastro.2018.12.023. Epub 2019 Jan 6.
PMID:
30625297
Free Article
Similar articles
Select item 12487388
69.
Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
Wheat LJ, Farthing C, Cohen C, Pierone G, Lalezari J, Pilson RS, Siemon-Hryczyk P; TIDBID (NR15520/M61018) study team.
Antivir Ther. 2002 Sep;7(3):199-209.
PMID:
12487388
Similar articles
Select item 8603981
70.
Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug.
Cherrington JM, Miner R, Hitchcock MJ, Lalezari JP, Drew WL.
J Infect Dis. 1996 Apr;173(4):987-92.
PMID:
8603981
Similar articles
Select item 8097082
71.
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame PT, Remick SC, Salgo MP, Lin AH, Nauss-Karol C, Lieberman J, Soo W.
Ann Intern Med. 1993 May 15;118(10):762-9.
PMID:
8097082
Similar articles
Select item 9350724
72.
Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay.
Chernoff DN, Miner RC, Hoo BS, Shen LP, Kelso RJ, Jekic-McMullen D, Lalezari JP, Chou S, Drew WL, Kolberg JA.
J Clin Microbiol. 1997 Nov;35(11):2740-4.
PMID:
9350724
Free PMC Article
Similar articles
Select item 9291334
73.
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.
Chou S, Marousek G, Guentzel S, Follansbee SE, Poscher ME, Lalezari JP, Miner RC, Drew WL.
J Infect Dis. 1997 Sep;176(3):786-9.
PMID:
9291334
Similar articles
Select item 8077713
74.
Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.
Lalezari JP, Drew WL, Glutzer E, Miner D, Safrin S, Owen WF Jr, Davidson JM, Fisher PE, Jaffe HS.
J Infect Dis. 1994 Sep;170(3):570-2.
PMID:
8077713
Similar articles
Select item 7637721
75.
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group.
Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, Benson CA, Friedberg DN, Hubbard L, Stempien MJ, et al.
N Engl J Med. 1995 Sep 7;333(10):615-20.
PMID:
7637721
Free Article
Similar articles
Select item 7574510
76.
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJ, Jaffe HS.
Antimicrob Agents Chemother. 1995 Jun;39(6):1247-52.
PMID:
7574510
Free PMC Article
Similar articles
Select item 7706804
77.
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.
Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, et al.
J Infect Dis. 1995 Apr;171(4):788-96.
PMID:
7706804
Similar articles
Select item 15125875
78.
Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
Wheeler DA, Lalezari JP, Kilby JM, Wheat J, Delehanty J, DeMasi R, Patel I, Salgo M.
J Clin Virol. 2004 Jun;30(2):183-90.
PMID:
15125875
Similar articles
Select item 9768631
79.
Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group.
Lalezari J.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):195-7. No abstract available.
PMID:
9768631
Similar articles
Select item 9764801
80.
Comparison of zidovudine phosphorylation in lymph nodes and peripheral blood mononuclear cells in HIV-infected patients. DATRI 012 Study Group.
Peter K, Lalezari JP, Pearl JM, Thevanayagam L, Gambertoglio JG.
AIDS. 1998 Sep 10;12(13):1729-31. No abstract available.
PMID:
9764801
81.
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.
Cherrington JM, Fuller MD, Lamy PD, Miner R, Lalezari JP, Nuessle S, Drew WL.
J Infect Dis. 1998 Dec;178(6):1821-5.
PMID:
9815243
Similar articles
Select item 11364910
82.
Drug-resistant herpes: cidofovir gel in limbo. Interview with Jay Lalezari, M.D. Interview by John S. James.
Lalezari J.
AIDS Treat News. 1997 Nov 21
No 283):5-6.
PMID:
11364910
Similar articles
Select item 8619596
83.
Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling.
Yuen GJ, Drusano GL, Fletcher C, Capparelli E, Connor JD, Lalezari JP, Drew L, Follansbee S, Busch D, Jacobson M, et al.
Antimicrob Agents Chemother. 1995 Oct;39(10):2350-2.
PMID:
8619596
Free PMC Article
Similar articles
Select item 24795200
84.
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study.
N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4.
PMID:
24795200
Free Article
Similar articles
Select item 10472478
85.
Cytomegalovirus: disease syndromes and treatment.
Drew WL, Lalezari JP.
Curr Clin Top Infect Dis. 1999;19:16-29. Review. No abstract available.
PMID:
10472478
Similar articles
Select item 8815677
86.
A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC).
Lalezari JP, Stagg RJ, Jaffe HS, Hitchcock MJ, Drew WL.
Adv Exp Med Biol. 1996;394:105-15. Review. No abstract available.
PMID:
8815677
Similar articles
Select item 22425702
87.
The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.
Hopkins S, DiMassimo B, Rusnak P, Heuman D, Lalezari J, Sluder A, Scorneaux B, Mosier S, Kowalczyk P, Ribeill Y, Baugh J, Gallay P.
J Hepatol. 2012 Jul;57(1):47-54. doi: 10.1016/j.jhep.2012.02.024. Epub 2012 Mar 13.
PMID:
22425702
Similar articles
Select item 28329334
88.
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
Wyles D, Saag M, Viani RM, Lalezari J, Adeyemi O, Bhatti L, Khatri A, King JR, Hu YB, Trinh R, Shulman NS, Ruane P.
J Infect Dis. 2017 Feb 15;215(4):599-605. doi: 10.1093/infdis/jiw597.
PMID:
28329334
Similar articles
Select item 20377413
89.
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.
Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.
J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190.
PMID:
20377413
Free PMC Article
Similar articles
Select item 25614962
90.
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; ALLY-3 Study Team.
Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10.
PMID:
25614962
Free PMC Article
Similar articles
Select item 9459896
91.
New treatment options for CMV retinitis in AIDS.
Lalezari JP.
Adv Nurse Pract. 1997 Apr;5(4):45-9, 83. Review. No abstract available.
PMID:
9459896
Similar articles
Select item 20660677
92.
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.
Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.
Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26.
PMID:
20660677
Free PMC Article
Similar articles
Select item 15179410
93.
Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients.
Zhang X, Lalezari JP, Badley AD, Dorr A, Kolis SJ, Kinchelow T, Patel IH.
Clin Pharmacol Ther. 2004 Jun;75(6):558-68.
PMID:
15179410
Similar articles
Select item 16213066
94.
A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.
de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, Brady RC, Shahmanesh M, Kinghorn G, Beutner KR, Patel R, Drehobl MA, Horner P, Kurtz TO, McDermott S, Wald A, Corey L.
Vaccine. 2006 Feb 13;24(7):914-20. Epub 2005 Sep 21.
PMID:
16213066
Similar articles
Select item 11262214
95.
Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.
Komanduri KV, Feinberg J, Hutchins RK, Frame RD, Schmidt DK, Viswanathan MN, Lalezari JP, McCune JM.
J Infect Dis. 2001 Apr 15;183( :1285-9. Epub 2001 Mar 12.
PMID:
11262214
Similar articles
Select item 8603962
96.
Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes.
Cohen OJ, Pantaleo G, Holodniy M, Fox CH, Orenstein JM, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, Cohn J, Novak R, McMahon D, Bilello J, Fauci AS.
J Infect Dis. 1996 Apr;173(4):849-56.
PMID:
8603962
Similar articles
Select item 23359516
97.
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO.
Hepatology. 2013 Jun;57(6):2143-54. doi: 10.1002/hep.26276.
PMID:
23359516
Similar articles
Select item 25483701
98.
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
Einstein MH, Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, Blatter MM, Lalezari J, David MP, Lin L, Struyf F, Dubin G; HPV-010 Study Group.
Hum Vaccin Immunother. 2014;10(12):3435-45. doi: 10.4161/hv.36121.
PMID:
25483701
Free PMC Article
Similar articles
Select item 9593141
99.
Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group.
Gnann JW Jr, Crumpacker CS, Lalezari JP, Smith JA, Tyring SK, Baum KF, Borucki MJ, Joseph WP, Mertz GJ, Steigbigel RT, Cloud GA, Soong SJ, Sherrill LC, DeHertogh DA, Whitley RJ.
Antimicrob Agents Chemother. 1998 May;42(5):1139-45.
PMID:
9593141
Free PMC Article
Similar articles
Select item 7597072
100.
Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.
Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, et al.
Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6017-21.
PMID:
7597072
101.
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A.
AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):685-93. Erratum in: AIDS Res Hum Retroviruses. 2003 Jan 1;19(1):83..
PMID:
12167274
Similar articles
Select item 8729649
102.
Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay method.
Peter K, Lalezari JP, Gambertoglio JG.
J Pharm Biomed Anal. 1996 Feb;14(4):491-9.
PMID:
8729649
https://www.ncbi.nlm.nih.gov/pubmed/?term=Lal...d=26423650
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Lalezari JP, Latiff GH, Brinson C, Echevarría J, Treviño-Pérez S, Bogner JR, Thompson M, Fourie J, Sussmann Pena OA, Mendo Urbina FC, Martins M, Diaconescu IG, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team.
Lancet HIV. 2015 Oct;2(10):e427-37. doi: 10.1016/S2352-3018(15)00177-0. Epub 2015 Sep 1.
PMID:
26423650
Similar articles
Select item 25942724
2.
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD.
JAMA. 2015 May 5;313(17):1736-44. doi: 10.1001/jama.2015.3868.
PMID:
25942724
Free Article
Similar articles
Select item 25839406
3.
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, Aguilar H, Felizarta F, McGovern B, King M, Polepally AR, Cohen DE.
J Hepatol. 2015 Aug;63(2):364-9. doi: 10.1016/j.jhep.2015.03.029. Epub 2015 Apr 1.
PMID:
25839406
Free Article
Similar articles
Select item 25038354
4.
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D; PHOTON-1 Investigators.
JAMA. 2014 Jul 23-30;312(4):353-61. doi: 10.1001/jama.2014.7734. Erratum in: JAMA. 2014 Nov 12;312(18):1932.
PMID:
25038354
Free PMC Article
Similar articles
Select item 23439365
5.
IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
Lalezari J, Box T, O'Riordan W, Mehra P, Nguyen T, Poordad F, Dejesus E, Kwo P, Godofsky E, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai J, Mayers D.
Antivir Ther. 2013;18(6):755-64. doi: 10.3851/IMP2552. Epub 2013 Feb 25.
PMID:
23439365
Similar articles
Select item 23070151
6.
Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection.
Lalezari J, Asmuth D, Casiró A, Vargas H, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai J, Mayers D.
Antimicrob Agents Chemother. 2012 Dec;56(12):6372-8. doi: 10.1128/AAC.01521-12. Epub 2012 Oct 15.
PMID:
23070151
Free PMC Article
Similar articles
Select item 25251156
7.
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.
Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, Freilich B, Zamparo J, Brown K, Dimitrova D, Kumar M, Manion D, Heath-Chiozzi M, Wolf R, Hughes E, Muir AJ, Hernandez AF.
Hepatology. 2015 Aug;62(2):409-16. doi: 10.1002/hep.27488. Epub 2015 May 26.
PMID:
25251156
Similar articles
Select item 25394038
8.
HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis.
Brinson C, Lalezari J, Gulam LH, Thompson M, Echevarria J, Treviño-Pérez S, Stock D, Samit JR, George HJ, Lataillade M.
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19529. doi: 10.7448/IAS.17.4.19529. eCollection 2014.
PMID:
25394038
Free PMC Article
Similar articles
Select item 21317794
9.
Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects.
Lalezari J, Gathe J, Brinson C, Thompson M, Cohen C, Dejesus E, Galindez J, Ernst JA, Martin DE, Palleja SM.
J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25. doi: 10.1097/QAI.0b013e318213c2c0.
PMID:
21317794
Similar articles
Select item 17617270
10.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B; DUET-1 study group.
Lancet. 2007 Jul 7;370(9581):29-38.
PMID:
17617270
Similar articles
Select item 16280695
11.
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP.
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):413-21.
PMID:
16280695
Similar articles
Select item 12138345
12.
A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
Lalezari J, Lindley J, Walmsley S, Kuppermann B, Fisher M, Friedberg D, Lalonde R, Matheron S, Nieto L, Torriani FJ, Van Syoc R, Sutton MA, Buhles W, Stempien MJ; Roche Valganciclovir Study Group.
J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):392-400.
PMID:
12138345
Similar articles
Select item 16135896
13.
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, Shachoy-Clark A, Adkison K, Demarest J, Lou Y, Berrey M, Piscitelli S.
AIDS. 2005 Sep 23;19(14):1443-8.
PMID:
16135896
Similar articles
Select item 25394039
14.
Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis.
Lalezari J, Latiff GH, Brinson C, Echevarria J, Treviño-Pérez S, Bogner JR, Stock D, Joshi SR, Hanna GJ, Lataillade M.
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19530. doi: 10.7448/IAS.17.4.19530. eCollection 2014.
PMID:
25394039
Free PMC Article
Similar articles
Select item 20935557
15.
Hepatic safety and tolerability in the maraviroc clinical development program.
Ayoub A, Alston S, Goodrich J, Heera J, Hoepelman AI, Lalezari J, Mchale M, Nelson M, van der Ryst E, Mayer H.
AIDS. 2010 Nov 13;24(17):2743-50. doi: 10.1097/QAD.0b013e32833f9ce2.
PMID:
20935557
Similar articles
Select item 19710593
16.
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups.
AIDS. 2009 Nov 13;23(17):2289-300. doi: 10.1097/QAD.0b013e3283316a5e.
PMID:
19710593
Similar articles
Select item 20134329
17.
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
Towner W, Lalezari J, Sension MG, Wohlfeiler M, Gathe J, Appelbaum JS, Bellman P, Gottlieb MS, Ryan R, Nijs S, Hoogstoel A, Van Solingen-Ristea R, Witek J.
J Acquir Immune Defic Syndr. 2010 Apr;53(5):614-8. doi: 10.1097/QAI.0b013e3181cdebb1.
PMID:
20134329
Similar articles
Select item 20300008
18.
Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.
Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C, Deeks SG.
J Acquir Immune Defic Syndr. 2010 Aug;54(4):389-93. doi: 10.1097/QAI.0b013e3181c42ea4.
PMID:
20300008
Free PMC Article
Similar articles
Select item 21078951
19.
Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
Hanna GJ, Lalezari J, Hellinger JA, Wohl DA, Nettles R, Persson A, Krystal M, Lin P, Colonno R, Grasela DM.
Antimicrob Agents Chemother. 2011 Feb;55(2):722-8. doi: 10.1128/AAC.00759-10. Epub 2010 Nov 15.
PMID:
21078951
Free PMC Article
Similar articles
Select item 19219022
20.
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.
Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA.
Nat Med. 2009 Mar;15(3):285-92. doi: 10.1038/nm.1932. Epub 2009 Feb 15.
PMID:
19219022
21.
Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.
N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.
PMID:
18832244
Free PMC Article
Similar articles
Select item 18266604
22.
Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
Lalezari J, Yadavalli GK, Para M, Richmond G, Dejesus E, Brown SJ, Cai W, Chen C, Zhong J, Novello LA, Lederman MM, Subramanian GM.
J Infect Dis. 2008 Mar 1;197(5):721-7. doi: 10.1086/527327.
PMID:
18266604
Similar articles
Select item 18315507
23.
Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection.
Jariwalla RJ, Lalezari J, Cenko D, Mansour SE, Kumar A, Gangapurkar B, Nakamura D.
J Altern Complement Med. 2008 Mar;14(2):139-46. doi: 10.1089/acm.2006.6397.
PMID:
18315507
Similar articles
Select item 26636929
24.
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.
Thompson M, Saag M, DeJesus E, Gathe J, Lalezari J, Landay AL, Cade J, Enejosa J, Lefebvre E, Feinberg J.
AIDS. 2016 Mar 27;30(6):869-78. doi: 10.1097/QAD.0000000000000988.
PMID:
26636929
Free PMC Article
Similar articles
Select item 25706092
25.
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T.
JAMA. 2015 Mar 24-31;313(12):1223-31. doi: 10.1001/jama.2015.1328.
PMID:
25706092
Similar articles
Select item 23183528
26.
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, Cornpropst MT, Mader M, Albanis E, Jiang D, Hebner CM, Symonds WT, Berrey MM, Lalezari J.
J Hepatol. 2013 Apr;58(4):663-8. doi: 10.1016/j.jhep.2012.11.018. Epub 2012 Nov 23.
PMID:
23183528
Similar articles
Select item 23717490
27.
A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.
Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Korman AJ, Lowy I.
PLoS One. 2013 May 22;8(5):e63818. doi: 10.1371/journal.pone.0063818. Print 2013.
PMID:
23717490
Free PMC Article
Similar articles
Select item 23797691
28.
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
Taiwo B, Acosta EP, Ryscavage P, Berzins B, Lu D, Lalezari J, Castro J, Adeyemi O, Kuritzkes DR, Eron JJ, Tsibris A, Swindells S.
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):167-73. doi: 10.1097/QAI.0b013e3182a03d95.
PMID:
23797691
Free PMC Article
Similar articles
Select item 22738014
29.
Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects.
Hicks C, Clay P, Redfield R, Lalezari J, Liporace R, Schneider S, Sension M, McRae M, Laurent JP.
AIDS Res Hum Retroviruses. 2013 Feb;29(2):250-5. doi: 10.1089/AID.2012.0093. Epub 2012 Aug 27.
PMID:
22738014
Free PMC Article
Similar articles
Select item 21716073
30.
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, Stroder R, Chen S, Underwood M, Fujiwara T, Piscitelli S, Lalezari J.
AIDS. 2011 Sep 10;25(14):1737-45. doi: 10.1097/QAD.0b013e32834a1dd9.
PMID:
21716073
Similar articles
Select item 26423374
31.
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M.
Lancet HIV. 2015 Aug;2(
:e319-27. doi: 10.1016/S2352-3018(15)00114-9. Epub 2015 Jul 9. Erratum in: Lancet HIV. 2015 Aug;2( :e316. Lancet HIV. 2015 Oct;2(10):e416. PMID:
26423374
Similar articles
Select item 23499158
32.
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A.
Lancet Infect Dis. 2013 May;13(5):401-8. doi: 10.1016/S1473-3099(13)70033-1. Epub 2013 Mar 15.
PMID:
23499158
Similar articles
Select item 11590500
33.
Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
Lalezari JP, Beal JA, Ruane PJ, Cohen CJ, Jacobson EL, Sundin D, Leong WP, Raffanti SP, Wheeler DA, Anderson RD, Keiser P, Schrader SR, Goodgame JC, Steinhart CR, Murphy RL, Wolin MJ, Smith KA.
HIV Clin Trials. 2000 Nov-Dec;1(3):1-15.
PMID:
11590500
Similar articles
Select item 9036797
34.
Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial.
Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL, Jaffe HS.
Ann Intern Med. 1997 Feb 15;126(4):257-63.
PMID:
9036797
Similar articles
Select item 9525435
35.
Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS.
Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, Nelson R, Hardy WD, Kuppermann BD, Northfelt DW, Youle M, Johnson M, Lewis RA, Weinberg DV, Simon GL, Wolitz RA, Ruby AE, Stagg RJ, Jaffe HS.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):339-44.
PMID:
9525435
Similar articles
Select item 7769276
36.
Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group.
Spector SA, Busch DF, Follansbee S, Squires K, Lalezari JP, Jacobson MA, Connor JD, Jung D, Shadman A, Mastre B, et al.
J Infect Dis. 1995 Jun;171(6):1431-7.
PMID:
7769276
Similar articles
Select item 25395187
37.
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, Sundaraiyer V, Natuk R, Gurtman A, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
J Infect Dis. 2015 Jul 1;212(1):18-27. doi: 10.1093/infdis/jiu631. Epub 2014 Nov 13.
PMID:
25395187
Similar articles
Select item 18279104
38.
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.
Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ, Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE, Choudhri S.
J Interferon Cytokine Res. 2008 Feb;28(2):89-100. doi: 10.1089/jir.2007.0064.
PMID:
18279104
Similar articles
Select item 27188960
39.
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Kowdley KV, Nelson DR, Lalezari JP, Box T, Gitlin N, Poleynard G, Rabinovitz M, Ravendhran N, Sheikh AM, Siddique A, Bhore R, Noviello S, Rana K.
Liver Int. 2016 Nov;36(11):1611-1618. doi: 10.1111/liv.13165. Epub 2016 Jun 16.
PMID:
27188960
Similar articles
Select item 27922453
40.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
Thompson M, Lalezari JP, Kaplan R, Pinedo Y, Pena OAS, Cahn P, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team.
Antivir Ther. 2017;22(3):215-223. doi: 10.3851/IMP3112. Epub 2016 Dec 6.
PMID:
27922453
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group.
N Engl J Med. 2003 May 29;348(22):2175-85. Epub 2003 Mar 13. Erratum in: N Engl J Med. 2003 Sep 11;349(11):1100.
PMID:
12637625
Free Article
Similar articles
Select item 18507525
42.
An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).
Lalezari JP, Saag M, Walworth C, Larson P.
AIDS Res Hum Retroviruses. 2008 Jun;24(6):805-13. doi: 10.1089/aid.2007.0251.
PMID:
18507525
Similar articles
Select item 17491001
43.
Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.
Lalezari JP, Ward DJ, Tomkins SA, Garges HP.
J Antimicrob Chemother. 2007 Jul;60(1):170-4. Epub 2007 May 8.
PMID:
17491001
Similar articles
Select item 16433107
44.
Enfuvirtide for nurses: answering patient questions on activity, safety, and lifestyle impact.
Glutzer E, Lalezari JP.
J Assoc Nurses AIDS Care. 2005 Sep-Oct;16(5):26-34. Review.
PMID:
16433107
Similar articles
Select item 15747252
45.
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
Lalezari JP, Bellos NC, Sathasivam K, Richmond GJ, Cohen CJ, Myers RA Jr, Henry DH, Raskino C, Melby T, Murchison H, Zhang Y, Spence R, Greenberg ML, Demasi RA, Miralles GD; T1249-102 Study Group.
J Infect Dis. 2005 Apr 1;191(7):1155-63. Epub 2005 Feb 22.
PMID:
15747252
Similar articles
Select item 15148534
46.
Enfuvirtide.
Lalezari JP, Luber AD.
Drugs Today (Barc). 2004 Mar;40(3):259-69. Review.
PMID:
15148534
Similar articles
Select item 14518696
47.
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J.
Antivir Ther. 2003 Aug;8(4):279-87.
PMID:
14518696
Similar articles
Select item 12957192
48.
Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
Lalezari JP, Patel IH, Zhang X, Dorr A, Hawker N, Siddique Z, Kolis SJ, Kinchelow T.
J Clin Virol. 2003 Oct;28(2):217-22.
PMID:
12957192
Similar articles
Select item 12765160
49.
Clinical safety and efficacy of enfuvirtide (T-20), a new fusion inhibitor. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
Lalezari JP.
AIDS Read. 2003 Mar;13(3 Suppl):S9-13.
PMID:
12765160
Similar articles
Select item 12646792
50.
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM.
AIDS. 2003 Mar 28;17(5):691-8.
PMID:
12646792
Similar articles
Select item 11744430
51.
High dose oral ganciclovir treatment for cytomegalovirus retinitis.
Lalezari JP, Friedberg DN, Bissett J, Giordano MF, Hardy WD, Drew WL, Hubbard LD, Buhles WC, Stempien MJ, Georgiou P, Jung DT, Robinson CA; Roche Cooperative Oral Ganciclovir Study Group.
J Clin Virol. 2002 Feb;24(1-2):67-77.
PMID:
11744430
Similar articles
Select item 12183255
52.
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.
Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, Talarico CL, Shaw S, Jacobson MA, Drew WL.
Antimicrob Agents Chemother. 2002 Sep;46(9):2969-76.
PMID:
12183255
Free PMC Article
Similar articles
Select item 11176734
53.
Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials.
Lalezari J, Campion K, Keene O, Silagy C.
Arch Intern Med. 2001 Jan 22;161(2):212-7.
PMID:
11176734
Similar articles
Select item 9395363
54.
The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.
Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffe HS, Mulato AS, Lamy PD, Li W, Cherrington JM, Hellmann N, Kahn J.
J Infect Dis. 1997 Dec;176(6):1517-23.
PMID:
9395363
Similar articles
Select item 9333146
55.
A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.
Lalezari J, Schacker T, Feinberg J, Gathe J, Lee S, Cheung T, Kramer F, Kessler H, Corey L, Drew WL, Boggs J, McGuire B, Jaffe HS, Safrin S.
J Infect Dis. 1997 Oct;176(4):892-8.
PMID:
9333146
Similar articles
Select item 25394009
56.
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
Eron JJ, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C, Elion R, Blick G, Khatri A, Hu YB, Gibbons K, Fredrick L, Co M, D'Amico R, Da Silva-Tillmann B, Trinh R, Sulkowski MS.
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19500. doi: 10.7448/IAS.17.4.19500. eCollection 2014.
PMID:
25394009
Free PMC Article
Similar articles
Select item 9058615
57.
Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis.
Lalezari JP, Kuppermann BD.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14 Suppl 1:S27-31. Review.
PMID:
9058615
Similar articles
Select item 18433307
58.
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group.
Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993.
PMID:
18433307
Similar articles
Select item 20710052
59.
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
DeJesus E, Lalezari JP, Osiyemi OO, Ruane PJ, Ryan R, Kakuda TN, Witek J.
Antivir Ther. 2010;15(5):711-20. doi: 10.3851/IMP1562.
PMID:
20710052
Similar articles
Select item 24725238
60.
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators.
N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.
PMID:
24725238
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T.
PLoS Pathog. 2014 Apr 10;10(4):e1004071. doi: 10.1371/journal.ppat.1004071. eCollection 2014 Apr.
PMID:
24722454
Free PMC Article
Similar articles
Select item 9058614
62.
Cidofovir: a new therapy for cytomegalovirus retinitis.
Lalezari JP.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14 Suppl 1:S22-6. Review.
PMID:
9058614
Similar articles
Select item 16280694
63.
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP.
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12.
PMID:
16280694
Similar articles
Select item 27456384
64.
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ.
Gastroenterology. 2016 Oct;151(4):651-659.e1. doi: 10.1053/j.gastro.2016.07.020. Epub 2016 Jul 25.
PMID:
27456384
Similar articles
Select item 7859141
65.
Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients.
Drew WL, Anderson R, Lang W, Miner RC, Davis G, Lalezari J.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):289-91.
PMID:
7859141
Similar articles
Select item 17711378
66.
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP.
AIDS Patient Care STDS. 2007 Aug;21(
:533-43. PMID:
17711378
Similar articles
Select item 8618603
67.
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.
Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, Sparti PD, Havlir DV, Simpson G, Buhles W, Wong R, Stempien M.
N Engl J Med. 1996 Jun 6;334(23):1491-7.
PMID:
8618603
Free Article
Similar articles
Select item 30625297
68.
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.
Yuen MF, Gane EJ, Kim DJ, Weilert F, Yuen Chan HL, Lalezari J, Hwang SG, Nguyen T, Flores O, Hartman G, Liaw S, Lenz O, Kakuda TN, Talloen W, Schwabe C, Klumpp K, Brown N.
Gastroenterology. 2019 Apr;156(5):1392-1403.e7. doi: 10.1053/j.gastro.2018.12.023. Epub 2019 Jan 6.
PMID:
30625297
Free Article
Similar articles
Select item 12487388
69.
Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
Wheat LJ, Farthing C, Cohen C, Pierone G, Lalezari J, Pilson RS, Siemon-Hryczyk P; TIDBID (NR15520/M61018) study team.
Antivir Ther. 2002 Sep;7(3):199-209.
PMID:
12487388
Similar articles
Select item 8603981
70.
Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug.
Cherrington JM, Miner R, Hitchcock MJ, Lalezari JP, Drew WL.
J Infect Dis. 1996 Apr;173(4):987-92.
PMID:
8603981
Similar articles
Select item 8097082
71.
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame PT, Remick SC, Salgo MP, Lin AH, Nauss-Karol C, Lieberman J, Soo W.
Ann Intern Med. 1993 May 15;118(10):762-9.
PMID:
8097082
Similar articles
Select item 9350724
72.
Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay.
Chernoff DN, Miner RC, Hoo BS, Shen LP, Kelso RJ, Jekic-McMullen D, Lalezari JP, Chou S, Drew WL, Kolberg JA.
J Clin Microbiol. 1997 Nov;35(11):2740-4.
PMID:
9350724
Free PMC Article
Similar articles
Select item 9291334
73.
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.
Chou S, Marousek G, Guentzel S, Follansbee SE, Poscher ME, Lalezari JP, Miner RC, Drew WL.
J Infect Dis. 1997 Sep;176(3):786-9.
PMID:
9291334
Similar articles
Select item 8077713
74.
Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.
Lalezari JP, Drew WL, Glutzer E, Miner D, Safrin S, Owen WF Jr, Davidson JM, Fisher PE, Jaffe HS.
J Infect Dis. 1994 Sep;170(3):570-2.
PMID:
8077713
Similar articles
Select item 7637721
75.
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group.
Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, Benson CA, Friedberg DN, Hubbard L, Stempien MJ, et al.
N Engl J Med. 1995 Sep 7;333(10):615-20.
PMID:
7637721
Free Article
Similar articles
Select item 7574510
76.
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJ, Jaffe HS.
Antimicrob Agents Chemother. 1995 Jun;39(6):1247-52.
PMID:
7574510
Free PMC Article
Similar articles
Select item 7706804
77.
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.
Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, et al.
J Infect Dis. 1995 Apr;171(4):788-96.
PMID:
7706804
Similar articles
Select item 15125875
78.
Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
Wheeler DA, Lalezari JP, Kilby JM, Wheat J, Delehanty J, DeMasi R, Patel I, Salgo M.
J Clin Virol. 2004 Jun;30(2):183-90.
PMID:
15125875
Similar articles
Select item 9768631
79.
Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group.
Lalezari J.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):195-7. No abstract available.
PMID:
9768631
Similar articles
Select item 9764801
80.
Comparison of zidovudine phosphorylation in lymph nodes and peripheral blood mononuclear cells in HIV-infected patients. DATRI 012 Study Group.
Peter K, Lalezari JP, Pearl JM, Thevanayagam L, Gambertoglio JG.
AIDS. 1998 Sep 10;12(13):1729-31. No abstract available.
PMID:
9764801
81.
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.
Cherrington JM, Fuller MD, Lamy PD, Miner R, Lalezari JP, Nuessle S, Drew WL.
J Infect Dis. 1998 Dec;178(6):1821-5.
PMID:
9815243
Similar articles
Select item 11364910
82.
Drug-resistant herpes: cidofovir gel in limbo. Interview with Jay Lalezari, M.D. Interview by John S. James.
Lalezari J.
AIDS Treat News. 1997 Nov 21
No 283):5-6. PMID:
11364910
Similar articles
Select item 8619596
83.
Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling.
Yuen GJ, Drusano GL, Fletcher C, Capparelli E, Connor JD, Lalezari JP, Drew L, Follansbee S, Busch D, Jacobson M, et al.
Antimicrob Agents Chemother. 1995 Oct;39(10):2350-2.
PMID:
8619596
Free PMC Article
Similar articles
Select item 24795200
84.
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study.
N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4.
PMID:
24795200
Free Article
Similar articles
Select item 10472478
85.
Cytomegalovirus: disease syndromes and treatment.
Drew WL, Lalezari JP.
Curr Clin Top Infect Dis. 1999;19:16-29. Review. No abstract available.
PMID:
10472478
Similar articles
Select item 8815677
86.
A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC).
Lalezari JP, Stagg RJ, Jaffe HS, Hitchcock MJ, Drew WL.
Adv Exp Med Biol. 1996;394:105-15. Review. No abstract available.
PMID:
8815677
Similar articles
Select item 22425702
87.
The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.
Hopkins S, DiMassimo B, Rusnak P, Heuman D, Lalezari J, Sluder A, Scorneaux B, Mosier S, Kowalczyk P, Ribeill Y, Baugh J, Gallay P.
J Hepatol. 2012 Jul;57(1):47-54. doi: 10.1016/j.jhep.2012.02.024. Epub 2012 Mar 13.
PMID:
22425702
Similar articles
Select item 28329334
88.
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
Wyles D, Saag M, Viani RM, Lalezari J, Adeyemi O, Bhatti L, Khatri A, King JR, Hu YB, Trinh R, Shulman NS, Ruane P.
J Infect Dis. 2017 Feb 15;215(4):599-605. doi: 10.1093/infdis/jiw597.
PMID:
28329334
Similar articles
Select item 20377413
89.
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.
Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.
J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190.
PMID:
20377413
Free PMC Article
Similar articles
Select item 25614962
90.
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; ALLY-3 Study Team.
Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10.
PMID:
25614962
Free PMC Article
Similar articles
Select item 9459896
91.
New treatment options for CMV retinitis in AIDS.
Lalezari JP.
Adv Nurse Pract. 1997 Apr;5(4):45-9, 83. Review. No abstract available.
PMID:
9459896
Similar articles
Select item 20660677
92.
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.
Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.
Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26.
PMID:
20660677
Free PMC Article
Similar articles
Select item 15179410
93.
Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients.
Zhang X, Lalezari JP, Badley AD, Dorr A, Kolis SJ, Kinchelow T, Patel IH.
Clin Pharmacol Ther. 2004 Jun;75(6):558-68.
PMID:
15179410
Similar articles
Select item 16213066
94.
A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.
de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, Brady RC, Shahmanesh M, Kinghorn G, Beutner KR, Patel R, Drehobl MA, Horner P, Kurtz TO, McDermott S, Wald A, Corey L.
Vaccine. 2006 Feb 13;24(7):914-20. Epub 2005 Sep 21.
PMID:
16213066
Similar articles
Select item 11262214
95.
Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.
Komanduri KV, Feinberg J, Hutchins RK, Frame RD, Schmidt DK, Viswanathan MN, Lalezari JP, McCune JM.
J Infect Dis. 2001 Apr 15;183(
:1285-9. Epub 2001 Mar 12. PMID:
11262214
Similar articles
Select item 8603962
96.
Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes.
Cohen OJ, Pantaleo G, Holodniy M, Fox CH, Orenstein JM, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, Cohn J, Novak R, McMahon D, Bilello J, Fauci AS.
J Infect Dis. 1996 Apr;173(4):849-56.
PMID:
8603962
Similar articles
Select item 23359516
97.
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO.
Hepatology. 2013 Jun;57(6):2143-54. doi: 10.1002/hep.26276.
PMID:
23359516
Similar articles
Select item 25483701
98.
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
Einstein MH, Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, Blatter MM, Lalezari J, David MP, Lin L, Struyf F, Dubin G; HPV-010 Study Group.
Hum Vaccin Immunother. 2014;10(12):3435-45. doi: 10.4161/hv.36121.
PMID:
25483701
Free PMC Article
Similar articles
Select item 9593141
99.
Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group.
Gnann JW Jr, Crumpacker CS, Lalezari JP, Smith JA, Tyring SK, Baum KF, Borucki MJ, Joseph WP, Mertz GJ, Steigbigel RT, Cloud GA, Soong SJ, Sherrill LC, DeHertogh DA, Whitley RJ.
Antimicrob Agents Chemother. 1998 May;42(5):1139-45.
PMID:
9593141
Free PMC Article
Similar articles
Select item 7597072
100.
Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.
Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, et al.
Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6017-21.
PMID:
7597072
101.
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A.
AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):685-93. Erratum in: AIDS Res Hum Retroviruses. 2003 Jan 1;19(1):83..
PMID:
12167274
Similar articles
Select item 8729649
102.
Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay method.
Peter K, Lalezari JP, Gambertoglio JG.
J Pharm Biomed Anal. 1996 Feb;14(4):491-9.
PMID:
8729649
(10)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼